Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30642715 | 1.00 | OPRD1 (0.38) | OPRD1CYP2D6CYP3A4ALOX15SLC6A9 | |
| SCHEMBL5458868 | 1.00 | OPRD1 (0.38) | OPRD1CYP2D6CYP3A4ALOX15SLC6A9 | |
| SCHEMBL5450723 | 1.00 | OPRD1 (0.38) | OPRD1CYP2D6CYP3A4ALOX15SLC6A9 | |
| SCHEMBL24826487 | 0.84 | CYP2D6 (0.36) | OPRD1CYP2D6CYP3A4ALOX15TSHR | |
| SCHEMBL30872207 | 0.82 | OPRD1 (0.41) | OPRD1CYP3A4SLC6A9L3MBTL1CYP2C9 | |
| SCHEMBL2849250 | 0.82 | OPRD1 (0.36) | OPRD1CYP2D6CYP3A4ALOX15SLC6A9 | |
| SCHEMBL2850422 | 0.82 | OPRD1 (0.36) | OPRD1CYP2D6CYP3A4ALOX15SLC6A9 | |
| SCHEMBL2849251 | 0.82 | OPRD1 (0.36) | OPRD1CYP2D6CYP3A4ALOX15SLC6A9 | |
| SCHEMBL5742744 | 0.81 | CYP2D6 (0.48) | OPRD1CYP2D6CYP3A4SLC6A9MEN1 | |
| SCHEMBL5744342 | 0.80 | CYP2D6 (0.39) | OPRD1CYP2D6CYP3A4ALOX15SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368616-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2025-12-04 | — | — | US | disclosed |
| US-20250206718-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| WO-2025037229-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | NOVARTIS AG (CH) | 2025-02-20 | — | — | WO | disclosed |
| EP-4495110-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2025-01-22 | — | — | EP | disclosed |
| EP-4393916-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| EP-4358942-A1 | PHARMACEUTICAL COMPOSITIONS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR | Blueprint Medicines Corporation (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-4359400-A1 | SALT AND CRYSTAL FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR | Blueprint Medicines Corporation (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2024008048-A1 | NOVEL PYRIMIDINE OR TRIAZINE-SUBSTITUTED PYRIDOHETEROCYCLIC COMPOUND | 杭州德睿智药科技有限公司 | 2024-01-11 | — | — | WO | disclosed |
| WO-2023174406-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2023-09-21 | — | — | WO | disclosed |
| WO-2023160638-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-08-31 | — | — | WO | disclosed |
| EP-1288198-A1 | PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS | KANEKA CORPORATION (JP) | 2003-03-05 | — | — | EP | disclosed |
| EP-0406112-B1 | 1-Benzhydrylazetidines, their preparation and their use as intermediates for the preparation of compounds with antimicrobial activity | ESTEVE LABOR DR (ES) | 1994-12-28 | — | — | EP | disclosed |
| US-5183902-A | Muscle relaxants | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-02-02 | — | — | US | disclosed |
| US-5151418-A | Muscle relaxants | A. H. ROBINS COMPANY, INCORPORATED (US) | 1992-09-29 | — | — | US | disclosed |
| US-5073646-A | Chemical intermediates, microbiocides | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1991-12-17 | — | — | US | disclosed |
| US-5068231-A | Ureas and thioureas for relaxing muscles | A. H. ROBINS COMPANY INCORPORATED (US) | 1991-11-26 | — | — | US | disclosed |
| EP-0406112-A1 | 1-Benzhydrylazetidines, their preparation and their use as intermediates for the preparation of compounds with antimicrobial activity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1991-01-02 | — | — | EP | disclosed |
| US-4956359-A | CARBOXAMIDES OR THIOCARBOXAMIDES OF ARYL OXY OR THIO AZETIDINES | A. H. ROBINS COMPANY, INC. (US) | 1990-09-11 | — | — | US | disclosed |
| EP-0194112-B1 | 3-ARYL-OXYAZETIDINECARBOXAMIDES HAVING ANTI-MUSCLE TENSION, ANTI-MUSCLE SPASTICITY, ANTICONVULSANT AND ANTIEPILECTIC ACTIVITY | A.H. ROBINS COMPANY, INCORPORATED (US) | 1990-05-23 | — | — | EP | disclosed |
| EP-0194112-A1 | 3-Aryl-oxyazetidinecarboxamides having anti-muscle tension, anti-muscle spasticity, anticonvulsant and antiepilectic activity | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206718-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, EGFR, WEE2 | OPRD1 3231/4885CYP2D6 363/4885CYP3A4 303/4885 |
| US-20250368616-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, EGFR | OPRD1 2895/4885CYP2D6 609/4885CYP3A4 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.